AUTHORS
Kareem Mosaheb, Nick Paciaroni, PhD2, Matthew Lei, PharmD3, Shayna Sarosiek, MD4, Andrew Branagan, MD, PhD5
AFFILIATIONS
1 Massachusetts General Hospital, Boston, Massachusetts, United States
2 The Binding Site, Birmingham, United Kingdom
3 Massachusetts General Hospital, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Massachusetts General Hospital, Boston, Massachusetts, United States
ABSTRACT
Background:
As increasingly effective frontline therapy produces deeper responses in Waldenström’s Macroglobulinemia (WM), conventional electrophoretic methods progressively reach their analytical limits, making continued response assessment of residual monoclonal protein (MP) more challenging. Mass spectrometry (MS) has the potential to extend measurable disease assessment beyond the analytical limits of electrophoresis. We performed a preliminary translational analysis of MS in patients enrolled in the ongoing, prospective ZEBRA trial for WM. ZEBRA is an investigator-initiated, multicenter, open-label, single-arm phase 2 study of zanubrutinib, bendamustine and rituximab (ZBR) in symptomatic, previously untreated WM at five US sites in the WM-NET network (NCT06561347).
Methods:
Serial serum samples collected prospectively during the phase II ZEBRA trial were analyzed by MALDI-TOF MS (the EXENTTM System, The Binding Site, part of Thermo Fisher Scientific) and compared with standard laboratory monitoring including serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE). Paired samples obtained during treatment (screening, cycle 6 [C6], cycle 12 [C12], and after 15 cycles at end of treatment [EOT]) were evaluated for concordance between methodologies and for the ability of MS to quantify or detect residual monoclonal IgM after SPEP became non-quantifiable (N/Q). Longitudinal patient-level analyses were performed to characterize residual MP kinetics during treatment. Detection and quantification of the anti-CD20 monoclonal antibody, rituximab, was also investigated.
Results:
Seventy-two paired serum samples from 39 patients with newly diagnosed WM enrolled in the ZEBRA trial were included in this preliminary analysis. Conventional SPEP and MS demonstrated concordant quantitative detection in 82% (59/72) of samples. Among 13 samples in which SPEP was either N/Q or negative, MS remained positive in 69% (9/13) of samples, including one sample also negative by IFE. The remaining four samples (31%) were negative by all methods. At the patient level, 13% (5/39) of patients had at least one follow-up timepoint in which SPEP was N/Q while MS remained positive.
During early treatment, reductions in MP measured by MS closely paralleled those observed by electrophoresis. As patients achieved deeper responses, SPEP increasingly reached its analytical limit, whereas MS provided quantitative or qualitative assessment of residual MP. Among seven samples that were positive by IFE but N/Q by SPEP, the median MP concentration by MS was 0.17 g/L (IQR: 0.088-0.456 g/L), demonstrating persistent measurable disease by MS.
In one representative patient, SPEP became N/Q at C12 before a measurable MP reappeared at EOT, whereas MS was continuously positive and demonstrated increasing MP concentration between C12 and EOT (0.17 to 0.59 g/L), permitting uninterrupted assessment of disease kinetics. MS also identified and quantified rituximab as a distinct therapeutic monoclonal antibody in 39% (28/72) of post-treatment samples, without obscuring identification of the endogenous MP.
Conclusions:
This preliminary analysis from the prospective ZEBRA trial demonstrates that MS may refine longitudinal response monitoring by extending measurable MP assessment beyond the quantification limits of electrophoresis during deeper responses. As longitudinal follow-up of the ZEBRA cohort matures, future analyses will determine whether persistent MS positivity and residual quantitative MP are associated with relapse risk, progression-free survival or refinement of conventional response criteria.
DISCLOSURES
Andrew Branagan, MD, PhD: No relevant conflicts of interest to declare.